TPSTTempest TherapeuticsNot started yet
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
Hepatocellular Carcinoma (HCC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 740 (planned)
- Started
- Dec 2025
- Main results expected
- Dec 2028
- Fully finished
- Jul 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: The time from randomization to death from any cause up to 60 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06680258 · record last updated 2025-09-03 · checked 2026-11-09 15:42 UTC